PI3K inhibitors
CN122295091APending Publication Date: 2026-06-26COGENT BIOSCIENCES
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- COGENT BIOSCIENCES
- Filing Date
- 2024-07-26
- Publication Date
- 2026-06-26
AI Technical Summary
Technical Problem
Existing therapeutic PI3K pathway inhibitors face problems of poor drug tolerance and drug resistance when treating cancers driven by PI3K alterations, necessitating the development of potent PI3K inhibitors.
Method used
Provide compounds with specific structures and their pharmaceutically acceptable salts, used alone or in combination with other therapeutic agents, for the treatment of cancers driven by PI3K alterations.
Benefits of technology
It effectively inhibits PI3K signaling, improves the efficacy of cancer treatment, and reduces drug tolerance and resistance.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122295091A_ABST
Abstract
A compound having the structure of formula (I): (I) or a stereoisomer of said compound, a tautomer of said compound, or a pharmaceutically acceptable salt thereof, wherein: R 1 R 2 R 3 R 4 R 5 R 8 A, X, Z, and Y are as defined herein. Pharmaceutical compositions comprising the said compounds and their use in methods of treating diseases are also described.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Method of packaging and sterilizing a pharmaceutical product
US5033252A
Packaged pharmaceutical product
US5052558A
Child resistant package assembly for dispensing pharmaceutical medications
US5323907A